SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $288.28M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 0.89M
Average 0.76M
SABS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
SAB Biotherapeutics, Inc.NASDAQ: SABS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $7.21M rose 163.4% year over year, ahead of the +116.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at -3.8% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $1.31M (-91.0%) for the fiscal year ending Dec 2026, a slowdown from the +57.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $7.21M+22.8% QoQ
- Last fiscal yearDec 2025
- $14.6M+57.4% YoY
- LTMJun 2026
- $21.82M+116.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 14.6M USD
- Year-over-year change
- +57.4%
- 4-year CAGR
- -3.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.6M | +57.4% |
| FY2024 | 2024-12-31 | 9.28M | -61.0% |
| FY2023 | 2023-12-31 | 23.8M | +45.3% |
| FY2022 | 2022-12-31 | 16.38M | -4.1% |
| FY2021 | 2021-12-31 | 17.09M | — |
Selling, General & Admin vs competitors
How SABS compares with its peers on the latest reported figures
- SABS's LTM Jun 2026 selling, general & admin of $21.82M is the 2nd highest of the 5 companies compared; the peer median is $17.66M.
- Its year-over-year change of +116.7% is the highest of 5, against a peer median of -6.5%.
- Over three fiscal years its annual growth of -3.8% compares with a peer median of +23.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.36M | -29.2% | +26.5% | 97.8% | |
| LTM Jun 2026 | $21.82M | +116.7% | -3.8% | — | |
| LTM Mar 2026 | $18.25M | -6.2% | +26.2% | — | |
| LTM Mar 2026 | $17.08M | -4.8% | +20.7% | 31.8% | |
| LTM Mar 2026 | $13.3M | -6.8% | +1.5% | — | |
| Peer median (excluding SABS) | $17.66M | -6.5% | +23.4% | 64.8% | |
Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 60.88M | 23.9M | 2.24M | 1.32M | 0 |
| Cost of Revenue | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Gross Profit | 59.22M | 20.61M | (1.51M) | (3.47M) | (3.08M) |
| Gross Margin | 97.3% | 86.2% | -67.3% | -262.4% | — |
| Research & Development | 57.18M | 36.44M | 16.52M | 30.16M | 34.35M |
| Selling, General & Admin | 17.09M | 16.38M | 23.8M | 9.28M | 14.6M |
| Operating Expenses | 72.62M | 49.53M | 36.57M | 39.44M | 45.87M |
| Depreciation & Amortization | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| EBITDA | (15.2M) | (15.12M) | (38.13M) | (28.99M) | 16.6M |
| EBITDA Margin | -25.0% | -63.3% | -1703.1% | -2192.5% | — |
| Operating Income | (13.39M) | (28.92M) | (38.08M) | (42.91M) | (48.95M) |
| Operating Margin | -22.0% | -121.0% | -1700.5% | -3244.9% | — |
| Interest Income | 23.12K | 71.07K | 584.97K | 1.29M | 1.43M |
| Interest Expense | 294.46K | 301.58K | 315.28K | 318.4K | 240.66K |
| Other Income / Expenses | (3.75M) | 10.2M | (4.12M) | 8.81M | 62.23M |
| Income Before Tax | (17.15M) | (18.72M) | (42.19M) | (34.11M) | 13.27M |
| Pre-Tax Margin | -28.2% | -78.3% | -1884.5% | -2579.0% | — |
| Income Tax Expense | 0 | 25.63K | 0 | 0 | 0 |
| Net Income | (17.15M) | (18.74M) | (42.19M) | (34.11M) | 13.27M |
| Net Margin | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
| EPS (Basic) | (3.94) | (4.31) | (7.64) | (3.68) | 0.22 |
| EPS (Diluted) | (6.30) | (4.31) | (7.64) | (3.68) | (0.79) |
| Weighted Avg Shares | 4.35M | 4.35M | 5.52M | 9.26M | 19.31M |
| Weighted Avg Shares (Diluted) | 2.73M | 4.35M | 5.52M | 9.26M | 61.34M |
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.